Literature DB >> 3004548

Immunological analysis of the specificity of the autologous humoral response in breast cancer patients.

A M Campbell, M A McCormack, C A Ross, R E Leake.   

Abstract

The autologous and allogeneic immunological humoral response of breast cancer patients to breast tumours was investigated by ELISA assay of both the serum and the supernatants of transformed lymphocytes from the patients and controls. No specificity or increased titre relative to the controls was observed in serum antibody. However, when the response was dissected by the use of clones of transformed lymphocytes from the patients, considerable specificity could be demonstrated in certain clones while other clones showed a generalised specificity which contributed to the masking of the specific response in the serum. Some of these clones may have clinical potential as diagnostic and prognostic tools.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004548      PMCID: PMC2001459          DOI: 10.1038/bjc.1986.2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  International workshop on monoclonal antibodies and breast cancer. San Francisco, California; November 8 and 9, 1984.

Authors:  J A Peterson; R L Ceriani
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  Nuclear localization of unoccupied oestrogen receptors.

Authors:  W V Welshons; M E Lieberman; J Gorski
Journal:  Nature       Date:  1984 Feb 23-29       Impact factor: 49.962

3.  Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization.

Authors:  L Winger; C Winger; P Shastry; A Russell; M Longenecker
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

4.  Clinical aspects of steroid receptor assays.

Authors:  R E Leake
Journal:  Med Lab Sci       Date:  1984-07

5.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.

Authors:  W A Knight; R B Livingston; E J Gregory; W L McGuire
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

6.  Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines.

Authors:  D Kozbor; A E Lagarde; J C Roder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

7.  The value of estrogen and progesterone receptors in the treatment of breast cancer.

Authors:  C K Osborne; M G Yochmowitz; W A Knight; W L McGuire
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

8.  Relationship of oestrogen-receptor status to survival in breast cancer.

Authors:  H M Bishop; R W Blamey; C W Elston; J L Haybittle; R I Nicholson; K Griffiths
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

Review 9.  Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies.

Authors:  P A Edwards
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

10.  Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.

Authors:  R E Leake; L Laing; K C Calman; F R Macbeth; D Crawford; D C Smith
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

  10 in total
  3 in total

1.  B-lymphocytes from melanoma patients and normal individuals react with melanoma cells but also with irrelevant antigens.

Authors:  B E Damato; A M Campbell; B J McGuire; W R Lee; W S Foulds
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

Review 2.  Human monoclonal antibodies and monoclonal antibody multispecificity.

Authors:  A M Campbell; P Whitford; R E Leake
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

Review 3.  Drug-targeting by monoclonal antibodies.

Authors:  M J Embleton
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.